Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli

Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli

Copyright 2000 Academic Press.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 98(2001), 2 vom: 15. Feb., Seite 280-92
1. Verfasser: Chen, B (VerfasserIn)
Weitere Verfasser: Stiff, P, Sloan, G, Kash, J, Manjunath, R, Pathasarathy, M, Oldenburg, D, Foreman, K E, Nickoloff, B J
Format: Aufsatz
Sprache:English
Veröffentlicht: 2001
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Comparative Study Journal Article Antigens, CD Antigens, CD34 B7-1 Antigen B7-2 Antigen CD86 protein, human HLA-DR Antigens Immunoglobulins Interferon-alpha mehr... Membrane Glycoproteins Membrane Proteins Recombinant Proteins Tumor Necrosis Factor-alpha flt3 ligand protein Granulocyte Colony-Stimulating Factor 143011-72-7 CD40 Ligand 147205-72-9 Filgrastim PVI5M0M1GW
LEADER 01000caa a22002652 4500
001 NLM110753054
003 DE-627
005 20250202105151.0
007 tu
008 231222s2001 xx ||||| 00| ||eng c
028 5 2 |a pubmed25n0370.xml 
035 |a (DE-627)NLM110753054 
035 |a (NLM)11161986 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Chen, B  |e verfasserin  |4 aut 
245 1 0 |a Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli 
264 1 |c 2001 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 29.03.2001 
500 |a Date Revised 13.12.2023 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 2000 Academic Press. 
520 |a Dendritic cells (DCs), generated ex vivo from blood mononuclear cells (PBMC) or CD34(+) stem cells, are being used to develop novel immunotherapies. To establish optimal DC generation, a direct comparison of the optimal cell source, culture conditions, and maturation stimuli was performed, utilizing phenotypic and functional assays as end points. Plastic adherent monocytes from PBMC were expanded in a serum-free medium (X-Vivo 10) for 7 days using GM-CSF/IL-4; CD34(+) cells were expanded for 14 days using GM-CSF/IL-4/ Flt3L, in either X-Vivo 10 alone or with albumin or autologous plasma. Expanded DC from both cell sources were matured for 7 days with CD40L or IFN-alpha/TNF-alpha. Starting from 2 x 10(7) monocytes, the optimal expansion/maturation process yielded 1.73 +/- 0.52 x 10(6) CD86(+) DC. Optimal expansion of CD34(+) cells (83.9 +/- 25.0-fold) was achieved using X-Vivo 10 with 5% plasma, matured with CD40L, and yielded 10.68 +/- 2.72 x 10(6) CD86(+) DC from 1 x 10(6) CD34(+) cells. Mature DC from PBMC or CD34(+) cells had similar enhanced expression of MHC class II HLA-DR, CD80, CD83, and CD86 and were potent stimulators of mixed lymphocyte reactions. Prior to maturation, all groups of DC actively phagocytosed apoptotic melanoma cells (approximately 50% of HLA-DR(+)). CD34(+) DC matured with CD40L or IFN-alpha/TNF-alpha had reduced phagocytic capability (34 and 31% of HLA-DR(+) DC, respectively). Similar expansion and functional activity was found using cryopreserved DC precursors, cultured in gas permeable bags. We conclude that both cell lineages produce potent mature DC, permitting exploration of the optimal clinical strategy to trigger anti-tumor immune responses in patients with malignancies 
650 4 |a Comparative Study 
650 4 |a Journal Article 
650 7 |a Antigens, CD  |2 NLM 
650 7 |a Antigens, CD34  |2 NLM 
650 7 |a B7-1 Antigen  |2 NLM 
650 7 |a B7-2 Antigen  |2 NLM 
650 7 |a CD86 protein, human  |2 NLM 
650 7 |a HLA-DR Antigens  |2 NLM 
650 7 |a Immunoglobulins  |2 NLM 
650 7 |a Interferon-alpha  |2 NLM 
650 7 |a Membrane Glycoproteins  |2 NLM 
650 7 |a Membrane Proteins  |2 NLM 
650 7 |a Recombinant Proteins  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a flt3 ligand protein  |2 NLM 
650 7 |a Granulocyte Colony-Stimulating Factor  |2 NLM 
650 7 |a 143011-72-7  |2 NLM 
650 7 |a CD40 Ligand  |2 NLM 
650 7 |a 147205-72-9  |2 NLM 
650 7 |a Filgrastim  |2 NLM 
650 7 |a PVI5M0M1GW  |2 NLM 
700 1 |a Stiff, P  |e verfasserin  |4 aut 
700 1 |a Sloan, G  |e verfasserin  |4 aut 
700 1 |a Kash, J  |e verfasserin  |4 aut 
700 1 |a Manjunath, R  |e verfasserin  |4 aut 
700 1 |a Pathasarathy, M  |e verfasserin  |4 aut 
700 1 |a Oldenburg, D  |e verfasserin  |4 aut 
700 1 |a Foreman, K E  |e verfasserin  |4 aut 
700 1 |a Nickoloff, B J  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 98(2001), 2 vom: 15. Feb., Seite 280-92  |w (DE-627)NLM098196855  |x 1521-6616  |7 nnns 
773 1 8 |g volume:98  |g year:2001  |g number:2  |g day:15  |g month:02  |g pages:280-92 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 98  |j 2001  |e 2  |b 15  |c 02  |h 280-92